BofA/Merrill Lynch downgraded Seattle Genetics (NASDAQ: SGEN) from Neutral to Underperform with a price target of $34.00 (from $40.00) on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE